Earnings summaries and quarterly performance for Repare Therapeutics.
Executive leadership at Repare Therapeutics.
Board of directors at Repare Therapeutics.
Research analysts covering Repare Therapeutics.
Recent press releases and 8-K filings for RPTX.
Repare Therapeutics Shareholders Approve Acquisition by XenoTherapeutics
RPTX
M&A
Proxy Vote Outcomes
- Repare Therapeutics Inc. shareholders approved the acquisition of the company by XenoTherapeutics, Inc. and Xeno Acquisition Corp. at a special meeting held on January 16, 2026.
- The special resolution for the acquisition was approved by 99.76% of the votes cast by shareholders.
- The acquisition is subject to approval by the Superior Court of Québec, with a hearing expected on January 23, 2026, and completion anticipated around January 28, 2026.
Jan 16, 2026, 10:10 PM
Repare Therapeutics Shareholders Approve XenoTherapeutics Acquisition
RPTX
M&A
Proxy Vote Outcomes
- Repare Therapeutics shareholders have approved the acquisition of the company by XenoTherapeutics, Inc., a non-profit biotechnology company, through a statutory plan of arrangement.
- The special resolution for the arrangement was approved by 99.76% of the votes cast by shareholders.
- The acquisition is subject to approval from the Superior Court of Québec, with the final order hearing expected on January 23, 2026, and completion anticipated around January 28, 2026.
- Shareholders also approved the voluntary liquidation and dissolution of the company by 99.75% of votes, in the event the arrangement is terminated.
Jan 16, 2026, 9:58 PM
Repare Therapeutics Announces Acquisition of RP-3467 by Gilead Sciences
RPTX
M&A
New Projects/Investments
Takeover Bid
- Repare Therapeutics Inc. has entered into an asset purchase agreement with Gilead Sciences, Inc. for the acquisition of its polymerase theta (Polθ) ATPase inhibitor, RP-3467, for up to $30 million in total consideration.
- The consideration includes a $25 million upfront payment and an additional $5 million payment upon completion of specified technology transfer activities. A $3 million holdback amount may also become payable after one year.
- This transaction has increased Repare's cash balance, leading to an estimated cash payment of approximately US$2.20 per Common Share for Repare shareholders at the closing of the previously announced arrangement with XenoTherapeutics, Inc..
- New York University consented to the assignment of Repare's license agreement to Gilead for a one-time payment of $250,000.
Dec 29, 2025, 12:00 PM
Repare Therapeutics Announces RP-3467 Acquisition by Gilead and Updated Shareholder Payout
RPTX
M&A
Takeover Bid
- Repare Therapeutics announced a definitive asset purchase agreement for Gilead Sciences to acquire its polymerase theta (Polθ) ATPase inhibitor, RP-3467, for up to $30 million in total consideration, including a $25 million upfront payment.
- This transaction represents Repare's third and most significant portfolio transaction this year.
- The upfront payment from the Gilead Agreement has increased Repare's cash balance, leading to an updated estimated cash payment of approximately US$2.20 per Common Share for Repare shareholders at the closing of the previously announced acquisition by XenoTherapeutics, Inc..
- Repare shareholders will hold a special meeting on January 16, 2026, to vote on the arrangement agreement with XenoTherapeutics, Inc..
Dec 24, 2025, 12:00 PM
Repare Therapeutics' sale to XenoTherapeutics under investigation
RPTX
M&A
Legal Proceedings
Takeover Bid
- Monteverde & Associates PC is investigating the sale of Repare Therapeutics Inc. (NASDAQ:RPTX) to XenoTherapeutics, Inc.
- Upon the closing of the proposed transaction, Repare shareholders are estimated to receive a cash payment of $1.82 per share, plus one non-transferable contingent value right.
- The law firm is questioning the fairness of the deal for shareholders.
Nov 28, 2025, 4:13 AM
RPTX Enters Arrangement Agreement with XenoTherapeutics and Xeno Acquisition Corp.
RPTX
M&A
Delisting/Listing Issues
Takeover Bid
- Repare Therapeutics Inc. (RPTX) entered into an Arrangement Agreement on November 14, 2025, with XENOTHERAPEUTICS, INC. and XENO ACQUISITION CORP. (the Purchaser).
- The agreement outlines the Contemplated Transactions, which include the Nasdaq Delisting of Repare Therapeutics Inc..
- The arrangement involves a distribution of a Cash Amount per Common Share to shareholders.
- Outstanding Options and RSUs will be vested and exchanged for a Cash Amount, and Options (where the cash amount exceeds the exercise price) will also receive one Contingent Value Right (CVR).
Nov 17, 2025, 2:18 PM
Repare Therapeutics Transaction with XenoTherapeutics Under Investigation by Ademi Firm
RPTX
Legal Proceedings
M&A
Takeover Bid
- The Ademi Firm is investigating Repare Therapeutics (RPTX) for potential breaches of fiduciary duty and other violations of law related to its recently announced transaction with XenoTherapeutics, Inc..
- Repare shareholders are expected to receive an estimated $1.82 per share in cash at closing and one non-transferable contingent value right (CVR) per share.
- The CVRs entitle shareholders to 90% to 75% of net proceeds from existing partnerships and potential asset dispositions over a 10-year period.
- The investigation also focuses on substantial benefits for Repare insiders from change of control arrangements and a significant penalty for competing bids, which may unreasonably limit other transactions.
Nov 15, 2025, 12:56 AM
Repare Therapeutics Enters Definitive Agreement to Be Acquired by XenoTherapeutics
RPTX
M&A
Earnings
Takeover Bid
- Repare Therapeutics Inc. has entered into a definitive arrangement agreement to be acquired by XenoTherapeutics, Inc..
- Under the terms of the agreement, Repare shareholders are estimated to receive a cash payment of US$1.82 per common share and one non-transferable Contingent Value Right (CVR) per common share.
- The transaction is expected to close in the first quarter of 2026.
- As of September 30, 2025, Repare Therapeutics reported $112.6 million in cash and cash equivalents and marketable securities.
- For the three months ended September 30, 2025, the company recorded a net income of $3.3 million.
Nov 14, 2025, 10:16 PM
Repare Therapeutics to be Acquired by XenoTherapeutics
RPTX
M&A
Delisting/Listing Issues
- Repare Therapeutics has entered into a definitive agreement to be acquired by XenoTherapeutics, Inc., with the transaction expected to close in the first quarter of 2026.
- Under the terms of the deal, Repare shareholders will receive approximately $1.82 per share in cash plus one non-transferable contingent value right (CVR) per common share, entitling them to future payments based on certain milestones and proceeds from partnerships.
- Following the acquisition announcement, Repare Therapeutics' stock price dropped by 2.37% to close at $1.65.
- Despite strong liquidity, Repare Therapeutics faces financial distress, indicated by a negative Altman Z-Score of -4.62, suggesting a bankruptcy risk within two years.
Nov 14, 2025, 9:51 PM
Pharma Equity Group Subsidiary Reponex Pharmaceuticals Receives Approval for RNX-011 Clinical Trial
RPTX
New Projects/Investments
- Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, received regulatory approval on September 1, 2025, to initiate a pivotal Phase 2 clinical trial for its drug candidate RNX-011.
- The study will investigate RNX-011 for the treatment of secondary peritonitis, a serious and life-threatening intra-abdominal infection.
- The trial is designed to demonstrate that RNX-011 can reduce serious postoperative complications and is expected to enroll 32 patients, with the first patient anticipated in Q4 2025.
- This approval is considered a crucial commercial milestone for Pharma Equity Group, strengthening its position for upcoming partner dialogues.
Sep 2, 2025, 8:04 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more